Nexium Ruling Could Hurt Antitrust Cases, FTC Tells 1st Circ.

By Matthew Bultman
February 16, 2016, 4:16 PM EST

The Federal Trade Commission waded into the pay-for-delay case over AstraZeneca's blockbuster heartburn drug Nexium on Friday, telling the First Circuit that a trial court's "erroneous analysis" in the case threatens...

Already a subscriber? Click here to view full article